Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 28;11(10):1458.
doi: 10.3390/cancers11101458.

PTEN and Gynecological Cancers

Camilla Nero  1 , Francesca Ciccarone  2 , Antonella Pietragalla  3 , Giovanni Scambia  4
Affiliations
Review

PTEN and Gynecological Cancers

Camilla Nero et al. Cancers (Basel). .

Abstract

PTEN is a tumour suppressor gene, and its loss of function is frequently observed in both heritable and sporadic cancers. It is involved in a great variety of biological processes, including maintenance of genomic stability, cell survival, migration, proliferation and metabolism. A better understanding of PTEN activity and regulation has therefore emerged as a subject of primary interest in cancer research. Gynaecological cancers are variously interested by PTEN deregulation and many perspective in terms of additional prognostic information and new therapeutic approaches can be explored. Here, we present the most significant findings on PTEN in gynaecological cancers (ovarian, endometrial, cervical, vulvar and uterine cancer) focusing on PTEN alterations incidence, biological role and clinical implications.

Keywords: PTEN; cervical cancer; endometrial cancer; ovarian cancer; uterine cancer; vulvar cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The incidence and type of PTEN alterations according to COSMIC and TGCA datasets in gynecological malignancies.
Figure 2
Figure 2
The incidence and type of PTEN alterations according to COSMIC and TGCA datasets in ovarian cancer.
Figure 3
Figure 3
The incidence and type of PTEN alterations according to COSMIC and TGCA datasets in endometrial cancer.
Figure 4
Figure 4
The incidence and type of PTEN alterations according to COSMIC and TGCA datasets in cervical cancer.
Figure 5
Figure 5
The incidence and type of PTEN alterations according to COSMIC dataset in vulvar cancer.
Figure 6
Figure 6
The incidence and type of PTEN alterations according to COSMIC and TGCA datasets in uterine cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009;4:127–150. doi: 10.1146/annurev.pathol.4.110807.092311. - DOI - PMC - PubMed
    1. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 1998;19:348–355. doi: 10.1038/1235. - DOI - PubMed
    1. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–390. doi: 10.1016/S0092-8674(00)80674-1. - DOI - PubMed
    1. Lee Y.R., Chen M., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor: New modes and prospects. Nat. Rev. Mol. Cell Biol. 2018;19:547–562. doi: 10.1038/s41580-018-0015-0. - DOI - PubMed
    1. Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113–3122. doi: 10.1038/sj.onc.1206451. - DOI - PubMed